Events - Slide 1 Events - Slide 2 Events - Slide 3 Events - Slide 4

Welcome to Retina Specialists Northwest

Dedicated to delivering compassionate excellence in retinal and inflammatory eye disease always.

Retina Specialists Northwest, PLLC is an ophthalmic subspecialty practice focused on Retina and Uveitis. The practice philosophy is summarized in the company motto: Compassionate Excellence Always.

Board certified eye physician and surgeon, Dr. Brenda Myers-Powell

Dr. Myers-Powell and her staff are committed to delivering the best in personalized retinal care efficiently and effectively. Our pledge is to understand you as a whole and to provide the best available medical and surgical treatment tailored to your needs. We are centrally located between Seattle and Tacoma, at West Campus in Federal Way, strategically positioned to deliver quality care to residents within and outside the metropolitan areas. Our office is easily accessible from I-5, Hwy-18, Hwy-167, and Hwy-99. For your convenience, we are open most Saturdays.

We utilize the latest technology as well as clinical expertise to diagnose and manage all retinal and inflammatory disorders with particular attention to Retinal Tear and Detachment, Disorders of the Vitreous, Macular Holes, Diabetic Retinopathy, Age-related Macular Degeneration, Retinal Vascular Disease, Macular Edema, Scleritis, and vision-threatening Uveitis.

Ultra-Widefield Multifocal Electroretinography and Visual Evoked Potentials

Retina Specialists Northwest is proud to announce the implementation of Diagnosys Ultra-Widefield Multifocal Electroretinography (mfERG) and Visual Evoked Potentials (VEP) as part of our service. This diagnostic tool can significantly benefit those with retinal and optic nerve disease.

Retina Specialists Northwest has invested in elevating the level of care in the Puget Sound area by providing a valuable service that had previously been unavailable in our community.

The mfERG can objectively assess cone dysfunction and macular disease facilitating diagnosis and assessment of progression of macular disorders such as Retinal Dystrophy, ARMD, Diabetic Retinopathy and Drug Toxicity. The AAO has listed mfERG as a critical test modality for screening for Plaquenil Toxicity.

VEP can assess optic nerve function, improving the diagnosis and management of Optic Neuritis and Optic Neuropathy. This is particularly useful in Multiple Sclerosis.

Our Federal Way office will provide this service at your patients' convenience.

Call (253) 517-3334 to schedule an appointment.

News from NEI

New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes

This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers, part of the Diabetic Retinopathy Clinical Research Network, say this is the first major advance in therapy in 40 years.

11/19/15 6:39 am

Lucentis Effective for Proliferative Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network ( compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.


11/11/15 7:28 am

Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.


10/13/15 10:24 am

National Advisory Eye Council Welcomes Three New Members

The National Eye Institute (NEI), part of NIH, has appointed three new members to the National Advisory Eye Council (NAEC) who are attending their first NAEC meeting as council members today. The NAEC provides guidance on research, training, and other NEI programs.

“Our new council members bring prodigious expertise,” said NEI director Paul A. Sieving, M.D., Ph.D. “They each have made major accomplishments in their respective fields, and we look forward to their input on strategies to advance the mission of NEI and the Audacious Goals Initiative.”


10/05/15 10:27 am

Scientists Test New Gene Therapy for Vision Loss From a Mitochondrial Disease

Researchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber hereditary optic neuropathy (LHON), and found that they can use gene therapy to improve visual function in the mice. LHON is one of many diseases tied to gene mutations that damage the tiny energy factories that power our cells, called mitochondria.


10/05/15 6:31 am